HEPA (Hepion Pharmaceuticals) Total Liabilities: $0.85 Mil (As of Mar. 2026)


What is Hepion Pharmaceuticals Total Liabilities?

Hepion Pharmaceuticals HEPA +39.50% Total Liabilities is $0.85 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Hepion Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $0.85 Mil.

Hepion Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 ($0.42 Mil) to Dec. 2025 ($0.40 Mil) but then increased from Dec. 2025 ($0.40 Mil) to Mar. 2026 ($0.85 Mil).

Hepion Pharmaceuticals's annual Total Liabilities declined from Dec. 2023 ($10.81 Mil) to Dec. 2024 ($3.48 Mil) and declined from Dec. 2024 ($3.48 Mil) to Dec. 2025 ($0.40 Mil).

Hepion Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Hepion Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals Total Liabilities Chart

Hepion Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.56 10.39 10.81 3.48 0.40

Hepion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.42 0.71 0.42 0.40 0.85

Hepion Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hepion Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.299+(0+0.103
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.40

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=3.07-2.668
=0.40

Hepion Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.736+(0+0.113
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.85

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2.706-1.857
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.85 Mil mean?
Hepion Pharmaceuticals (HEPA) has a Total Liabilities of $0.85 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hepion Pharmaceuticals and its competitors.
Is Hepion Pharmaceuticals' Total Liabilities too high?
Hepion Pharmaceuticals' current Total Liabilities is $0.85 Mil.
How does Hepion Pharmaceuticals' Total Liabilities compare to AXIM and ZVSA?
Hepion Pharmaceuticals' Total Liabilities of $0.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hepion Pharmaceuticals and its competitors. Hepion Pharmaceuticals's current Total Liabilities is $0.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (HEPA) has a current Total Liabilities of $0.85 Mil. The current Total Liabilities is $0.85 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Hepion Pharmaceuticals (HEPA), the current Total Liabilities is $0.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hepion Pharmaceuticals Business Description

Address 55 Madison Avenue, Suite 400- PMB 4362, Morristown, NJ, USA, 07960
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.